Supriya Lifescience is currently trading at Rs. 239.60, up by 0.65 points or 0.27% from its previous closing of Rs. 238.95 on the BSE.
The scrip opened at Rs. 242.50 and has touched a high and low of Rs. 246.35 and Rs. 235.05 respectively. So far 25764 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 310.00 on 11-Sep-2023 and a 52 week low of Rs. 170.05 on 27-Mar-2023.
Last one week high and low of the scrip stood at Rs. 255.50 and Rs. 235.05 respectively. The current market cap of the company is Rs. 1912.67 crore.
The promoters holding in the company stood at 68.30%, while Institutions and Non-Institutions held 12.51% and 19.19% respectively.
Supriya Lifescience has collaborated with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, to develop one of its kind oral cancer detection kit named Quickblue oral kit. This oral cancer detection kit is designed to detect oral cancer in a cost-effective and efficient manner.
This kit seamlessly detects oral cancer and could potentially reduce the need for extensive preclinical and clinical trials. The company has also filed for the patent of the Quickblue oral kit.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: